This startup's mission to extend human life sounds like sci-fi, and investors are betting $20M on it
Startup profile: Tolerance Bio
Founded by: Francisco Leon
Year founded: 2023
Headquarters: Philadelphia, PA
Sector: Life sciences
Funding and valuation: $20.2 million raised at an undisclosed valuation, according to the company
Key ecosystem partners: Columbus Venture Partners, Ben Franklin Technology Partners
When Francisco Leon talks about the medical science behind the biotech company he founded in 2023, it sounds like something out of a movie.
The company, Tolerance Bio, focuses on preserving the body's immune system by restoring the function of an organ called the thymus. The organ, long believed to be as useful in adults as the appendix (that is, not at all), may actually be the key to slower aging and prolonged life spans.
'Immune tolerance is at the core of almost all medical needs,' Leon told Technical.ly.
Now, Tolerance Bio is moving toward the first trials of its proprietary stem cell therapy, focusing first on children born without a thymus.
The thymus, a small gland located behind the breastbone in the upper chest, controls immune tolerance by creating T-cells, white blood cells that fight infections and cancerous cells, and can also prevent the body from attacking healthy cells.
It's a vital organ, but even in a perfectly healthy person, it only functions at 100% for the first two years of life, and then, Leon said, it starts to shrink.
By adulthood, the thymus functions at just 10%, which is why the medical community didn't think it was needed in adults.
That changed in 2023, when an article published in the New England Journal of Medicine concluded that the surgical removal of the residue of the thymus in adults led to an increase in the five-year mortality rates due to cancer and autoimmunity.
Subsequent research in nursing homes, Leon said, found that the better the thymic function, the lower the incidence of cancer, autoimmunity and infection.
'That's why we started the company,' Leon said, 'we are trying to restore thymic function.'
From genetic diseases to anti-aging
One of the main focuses of Tolerance Bio's research and development is using its cell implantation therapy to cure DiGeorge syndrome, also known as 22q11.2 deletion syndrome, a genetic condition where a baby is born without a thymus, or with one that is underdeveloped. Children with this condition struggle to fight infections and often have heart problems or other serious medical issues.
Restoring the thymus has the potential to save babies who, with cases of complete DiGeorge syndrome, have a life expectancy of two to three years without medical intervention.
Since the thymus naturally loses functionality as a person ages, Leon and his team also aim to develop treatments for adults, including a drug for healthy people that could potentially delay aging and increase longevity.
'We can regenerate the thymus by implanting cells intramuscularly; it's a new science,' Leon said.
It's yet to be proven in humans, but if they can show the principle in human patients, he said, they can potentially apply it to other conditions, including Type 1 diabetes, cancer, organ diseases, other immune deficiencies, and, potentially, Alzheimer's disease.
A $20 million seed round
Leon, who leads a hybrid team of 10 from Tolerance Bio headquarters at the B+labs incubator at the Cira Centre in Philadelphia, is an immunologist who came to the US from Spain 25 years ago.
After starting out working for pharmaceutical companies, including helping to develop drugs in immunology and oncology, he became an entrepreneur, cofounding the drug development companies Celimmune (acquired by Amgen in 2017) and Provention (acquired by Sanofi in 2023). Provention developed the drug Tzield, which can delay the onset of Type 1 diabetes in at-risk patients.
'It was the first drug ever to delay the onset of an autoimmune disease,' Leon said. 'You give it to children that show signs of being about to become diabetic, but still don't need insulin.'
By the time Sanofi acquired Provention, Leon was ready to turn his focus to preventing and regenerating the thymus. He started Tolerance Bio, initially as a concept, bringing two members of the Provention team with him and partnering with University of Florida academic Holger Russ as Tolerance Bio's scientific cofounder.
Tolerance Bio closed a $20.2 million seed round in December 2024. Led by Columbus Venture Partners, it included Ben Franklin Technology Partners, Criteria Bio Ventures, Sessa Capital, BioAdvance, Pacific 8 Ventures and individual biotechnology investors with an interest in thymus regeneration.
'We now know that thymic evolution is the main limiter of human life — it is the beginning of aging,' Leon said. 'There is a strong correlation between thymic function and longevity in humans and animals.'
'This almost sounds like science fiction'
Even the Tolerance Bio team is amazed at the potential.
'This almost sounds like science fiction, in some respects,' said Phil Ball, Tolerance Bio's SVP and head of business development and operations, who previously worked with Leon at Provention. 'The technology that science needed to get to this point is, even for me, who's worked in the industry for so long, is absolutely amazing.'
Translating that technology into actual products that reach as many patients as possible is a priority for the team.
'Ultimately, if we don't have approved products, it's been wasted time,' said Ball, who has spent 25 years in the industry, starting in the UK, where he worked for small biotech companies before moving to the US and eventually settling in Chapel Hill, North Carolina.
The team's expert on scaling up clinical manufacturing, Poh Yeh-Chuin, is based in Cambridge, Massachusetts. He previously worked for Beam Therapeutics, where he led a cell process development group that developed products currently being manufactured — one, a stem cell program for sickle cell disease, the other a CAR-T therapy program for cancer treatment.
Prior to that, he was part of the startup Semma Therapeutics (since acquired by Vertex), helping to develop a Type 1 diabetes treatment using pancreatic stem cells.
'It's very related to the work that we're doing here at Tolerance,' Poh said. 'Especially the cell therapy part, because both the pancreas as well as the thymus are derived from what we call the endoderm lineage.'
Simply put, the endocrine system — including the pancreas, the thymus and the thyroid — comes from the same type of embryonic cells, which can be used in the treatment of endocrine disorders.
Justin Vogel, Tolerance's chief financial officer and the other former Provention team member, grew up at the Jersey Shore and still lives in New Jersey. While the team is spread out, Vogel frequently comes to work at the Philadelphia office.
While much of what they do at Tolerance Bio is focused on complex biotechnology, Vogel also stressed the importance of getting involved with the people and organizations they are trying to help. Members of the team attended the recent 22q at The Zoo event in Philadelphia, part of a global awareness event held at zoos around the world led by the International 22q11.2 Foundation.
'We're a very patient-focused organization,' Vogel said. 'It's so important to hear all the stories and meet the families, and it really resonates with us and gives meaning to what we try to do for these kids.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Technical.ly
3 days ago
- Technical.ly
This startup's mission to extend human life sounds like sci-fi, and investors are betting $20M on it
Startup profile: Tolerance Bio Founded by: Francisco Leon Year founded: 2023 Headquarters: Philadelphia, PA Sector: Life sciences Funding and valuation: $20.2 million raised at an undisclosed valuation, according to the company Key ecosystem partners: Columbus Venture Partners, Ben Franklin Technology Partners When Francisco Leon talks about the medical science behind the biotech company he founded in 2023, it sounds like something out of a movie. The company, Tolerance Bio, focuses on preserving the body's immune system by restoring the function of an organ called the thymus. The organ, long believed to be as useful in adults as the appendix (that is, not at all), may actually be the key to slower aging and prolonged life spans. 'Immune tolerance is at the core of almost all medical needs,' Leon told Now, Tolerance Bio is moving toward the first trials of its proprietary stem cell therapy, focusing first on children born without a thymus. The thymus, a small gland located behind the breastbone in the upper chest, controls immune tolerance by creating T-cells, white blood cells that fight infections and cancerous cells, and can also prevent the body from attacking healthy cells. It's a vital organ, but even in a perfectly healthy person, it only functions at 100% for the first two years of life, and then, Leon said, it starts to shrink. By adulthood, the thymus functions at just 10%, which is why the medical community didn't think it was needed in adults. That changed in 2023, when an article published in the New England Journal of Medicine concluded that the surgical removal of the residue of the thymus in adults led to an increase in the five-year mortality rates due to cancer and autoimmunity. Subsequent research in nursing homes, Leon said, found that the better the thymic function, the lower the incidence of cancer, autoimmunity and infection. 'That's why we started the company,' Leon said, 'we are trying to restore thymic function.' From genetic diseases to anti-aging One of the main focuses of Tolerance Bio's research and development is using its cell implantation therapy to cure DiGeorge syndrome, also known as 22q11.2 deletion syndrome, a genetic condition where a baby is born without a thymus, or with one that is underdeveloped. Children with this condition struggle to fight infections and often have heart problems or other serious medical issues. Restoring the thymus has the potential to save babies who, with cases of complete DiGeorge syndrome, have a life expectancy of two to three years without medical intervention. Since the thymus naturally loses functionality as a person ages, Leon and his team also aim to develop treatments for adults, including a drug for healthy people that could potentially delay aging and increase longevity. 'We can regenerate the thymus by implanting cells intramuscularly; it's a new science,' Leon said. It's yet to be proven in humans, but if they can show the principle in human patients, he said, they can potentially apply it to other conditions, including Type 1 diabetes, cancer, organ diseases, other immune deficiencies, and, potentially, Alzheimer's disease. A $20 million seed round Leon, who leads a hybrid team of 10 from Tolerance Bio headquarters at the B+labs incubator at the Cira Centre in Philadelphia, is an immunologist who came to the US from Spain 25 years ago. After starting out working for pharmaceutical companies, including helping to develop drugs in immunology and oncology, he became an entrepreneur, cofounding the drug development companies Celimmune (acquired by Amgen in 2017) and Provention (acquired by Sanofi in 2023). Provention developed the drug Tzield, which can delay the onset of Type 1 diabetes in at-risk patients. 'It was the first drug ever to delay the onset of an autoimmune disease,' Leon said. 'You give it to children that show signs of being about to become diabetic, but still don't need insulin.' By the time Sanofi acquired Provention, Leon was ready to turn his focus to preventing and regenerating the thymus. He started Tolerance Bio, initially as a concept, bringing two members of the Provention team with him and partnering with University of Florida academic Holger Russ as Tolerance Bio's scientific cofounder. Tolerance Bio closed a $20.2 million seed round in December 2024. Led by Columbus Venture Partners, it included Ben Franklin Technology Partners, Criteria Bio Ventures, Sessa Capital, BioAdvance, Pacific 8 Ventures and individual biotechnology investors with an interest in thymus regeneration. 'We now know that thymic evolution is the main limiter of human life — it is the beginning of aging,' Leon said. 'There is a strong correlation between thymic function and longevity in humans and animals.' 'This almost sounds like science fiction' Even the Tolerance Bio team is amazed at the potential. 'This almost sounds like science fiction, in some respects,' said Phil Ball, Tolerance Bio's SVP and head of business development and operations, who previously worked with Leon at Provention. 'The technology that science needed to get to this point is, even for me, who's worked in the industry for so long, is absolutely amazing.' Translating that technology into actual products that reach as many patients as possible is a priority for the team. 'Ultimately, if we don't have approved products, it's been wasted time,' said Ball, who has spent 25 years in the industry, starting in the UK, where he worked for small biotech companies before moving to the US and eventually settling in Chapel Hill, North Carolina. The team's expert on scaling up clinical manufacturing, Poh Yeh-Chuin, is based in Cambridge, Massachusetts. He previously worked for Beam Therapeutics, where he led a cell process development group that developed products currently being manufactured — one, a stem cell program for sickle cell disease, the other a CAR-T therapy program for cancer treatment. Prior to that, he was part of the startup Semma Therapeutics (since acquired by Vertex), helping to develop a Type 1 diabetes treatment using pancreatic stem cells. 'It's very related to the work that we're doing here at Tolerance,' Poh said. 'Especially the cell therapy part, because both the pancreas as well as the thymus are derived from what we call the endoderm lineage.' Simply put, the endocrine system — including the pancreas, the thymus and the thyroid — comes from the same type of embryonic cells, which can be used in the treatment of endocrine disorders. Justin Vogel, Tolerance's chief financial officer and the other former Provention team member, grew up at the Jersey Shore and still lives in New Jersey. While the team is spread out, Vogel frequently comes to work at the Philadelphia office. While much of what they do at Tolerance Bio is focused on complex biotechnology, Vogel also stressed the importance of getting involved with the people and organizations they are trying to help. Members of the team attended the recent 22q at The Zoo event in Philadelphia, part of a global awareness event held at zoos around the world led by the International 22q11.2 Foundation. 'We're a very patient-focused organization,' Vogel said. 'It's so important to hear all the stories and meet the families, and it really resonates with us and gives meaning to what we try to do for these kids.'
Technical.ly
30-05-2025
- Technical.ly
How Lithero is using AI to speed up pharma marketing compliance
Startup profile: Lithero Founded by: Nyron Burke Year founded: 2015 Headquarters: Philadelphia, PA Sector: Life sciences, AI Funding and valuation: $0.68 million raised as of May 2022, according to PitchBook Key ecosystem partners: Ben Franklin Technology Partners, Morgan Lewis, Drexel University, University City Science Center, Broad Street Angels, Ic@3401 In life sciences, everything takes longer. Nyron Burke, cofounder and CEO of the Philadelphia-based AI for life sciences company Lithero, learned that through years of working as a consultant with pharmaceutical companies that were always looking for ways to speed up the process of creating marketing materials. What may seem relatively simple, like a pharmaceutical pamphlet for a doctor's office, can take months to finalize due to compliance issues. The final draft, with its medical language and side effects disclosures, has to be just right, requiring multiple reviews by medical lawyers before it goes to print. It's a stark contrast to consumer marketing, where a marketing professional might be able to create a one-pager in a day. 'With life sciences, that just wasn't possible,' Burke told noting that the extra time it takes to make biotech marketing materials compliant also increases the cost tenfold. Burke founded Lithero in 2015, years before AI became a common part of everyday life. He knew that machine learning could make the process considerably faster by screening for compliance issues before a medical lawyer reviews it, cutting down on the number of reviews — and, crucially, time. 'Divine intervention' led to the development of the engine Before Lithero, Burke spent eight years working for the global professional services company Accenture, with a focus on pharma and biotech companies. 'The three things I spent my consulting career on were speed, cost and compliance in pharma marketing specifically,' he said. 'But with the aspirations that my clients had, I had to not just do a good job, but to fundamentally do something that was transformative.' The speed he wanted for his clients was impossible in the 2010s — each human review for compliance was necessary, but time-consuming. AI, Burke said, had no hype around it in 2015 when he had the idea to use it to help achieve the speed he was looking for. The one thing holding him back was that he didn't know enough about AI to build an engine that could do what he needed to do. Then he met Brandon Morton, an AI researcher at Drexel who was working on his doctorate at the time. 'We met at church randomly,' Burke said. 'It was like divine intervention … His research is really what powered our ability to actually do what we're doing.' Morton effectively became a cofounder of Lithero. Even with his leadership, Burke said, it was a challenge. 'AI is very, very difficult,' Burke said. 'People don't appreciate the beauty and the power of the human mind and how hard it is to get machines to simulate what we do.' An AI assistant that doesn't hallucinate The technology Lithero created is called LARA, Lithero Artificial Review Assistant. 'You could think of it sort of like an artificial lawyer,' Burke said. Once LARA has all of a client's necessary information, it essentially pre-screens the content. It's not meant to replace the client's human lawyer, just to make it so that the lawyer has less to do on each individual piece of marketing. Then, he said, LARA will understand the client-specific content well enough that the client can use the tool for other things as well, such as creating annotations and comparing content to customer behavioral data. While today people tend to think of large language model generative AI like ChatGPT when they think of AI, LARA still isn't generative — it doesn't generate content based on prompts, it is a screening and correlation tool that can be trained to know everything about a specific brand. As such, it is not susceptible to drawbacks like hallucinations, when an AI model randomly answers with false information presented as fact, often a result of insufficient data or bias. The public launch of generative AI did help the company, though, by making the concept of an AI tool less obscure. 'It has normalized what we're doing,' Burke said. 'We're in a very conservative, cautious, slow industry — it changed the conversations that I was having.' Now, he says, there is a lot of demand, and a lot of clients bringing them new ideas on how the company can continue to grow. 'Our future is not just compliance, it's also creative,' Burke said. 'We recently launched some creative assistants, and are seeing this amazing amount of excitement.' From one to ten To get to where Lithero is today, with a team of ten and a growing roster of clients, it spent years based at Ic@3401, a University City coworking and incubation space sponsored by Drexel University and the University City Science Center that closed in 2024. One of its earliest investors, apart from friends and family, was Ben Franklin Technology Partners. Burke also credits its law firm Morgan Lewis as a big supporter, as well as angel investment group Broad Street Angels.
Technical.ly
08-05-2025
- Technical.ly
GoWell Benefits aims to take the stress out of employee health plans
Startup profile: GoWell Founded by: Holly Adams Year founded: 2021 Headquarters: Philadelphia, PA Sector: Insurance Funding and valuation: $2.83 million, according to PitchBook Key ecosystem partners: Ben Franklin Technology Partners, Naples Technology Ventures, Chloe Capital When Holly Adams worked as a benefits consultant helping businesses navigate health insurance enrollment, she knew there had to be a better way. For more than a decade, she watched as employers and employees struggled with complicated enrollment processes, long questionnaires and tech that wasn't as accessible as she knew it could be. 'I tried different things, even sending iPads to stores to see if they made it easier, but it just was a little bit too complicated for the average consumer,' Adams told She took what she'd learned and came up with GoWell Benefits, a platform launched in 2021 that simplifies the enrollment process for employers with an easy and accessible way to insure employees. 'We work with brokers and we work with employers, insurance carriers, and employees,' Adams said. 'All those entities touch our system to make insurance more transparent and a little bit easier to understand.' From early adoption to tech startup Adams started her career at the end of the 1990s, when tech was just starting to enter the workplace. Working for GlaxoSmithKline, she helped the company get its compliance data warehouse set up. Her job back then was to meet with developers to make sure that prescription data could be analyzed. While she would shift away from a technical job when she went into benefits consulting, that experience would come in handy when she decided to create GoWell. 'I had the opportunity to work with programmers and work towards realizing a dream,' Adams said, 'then I took that experience and used it to build my own dream.' The biggest hurdle, she said, is getting the enrollment process started. An employee who feels overwhelmed by enrolling before it even starts isn't going to be focused on what matters, like which deductibles meet their needs, which prescriptions are covered, co-pays and whether their chosen doctors are covered. 'Until you get that piece in, it's hard to try to make insurance more transparent, because people are trying to figure out how to do it, as opposed to what they should be focusing on, which is what they're getting,' she said. It's a holistic approach, she said, that meets employees where they are, engaging them and ultimately making it easier for the employer to track benefits. One of the 2% of VC-funded ventures Today, GoWell has about 10,000 users on its platform, a staff of 10 employees and has reached profitability. In the beginning, Adams used her own funds to support the startup, but funding eventually started coming in, including from its lead investors Ben Franklin Technology Partners and Naples Technology Ventures, as well as Chloe Capital, a VC firm that focuses on investing in women. 'They've been very supportive in helping us build out the technology and make it as a startup,' Adams said. 'We're really lucky because we're one of 2% of women [owned startups] that are funded.' So far GoWell has raised $2.85 million, according to Pitchbook. There are more funding rounds to come for GoWell, she said, with plans to use future investments to add more components to the platform, including AI. 'That's what we're developing now,' Adams said. 'Making our software more intuitive.'
